
What is claimed is:


1. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 10.55, 13.61 and 19.84° 2θ.


2. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.80, 17.29 and 21.74° 2θ.


3. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.83, 17.26 and 21.86° 2θ.


4. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 10.37, 13.41 and 19.52° 2θ.


5. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.92, 17.29 and 21.81° 2θ.


6. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 18.53, 20.85 and 21.10° 2θ.


7. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.51, 17.90 and 21.28° 2θ.


8. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.74, 17.22 and 21.76° 2θ.

9. A crystal form comprising Compound 1, or a tautomer thereof:




1

which has an X-ray powder diffraction pattern comprising peaks at approximately 7.94, 16.00 and 18.27° 2θ.

10. Use of a solid form of any one of claims 1-9 in the manufacture of a medicament for treating or preventing interstitial pulmory fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus.


11. Use of a solid form of any one of claims 1-9 in the manufacture of a medicament for treating or preventing liver fibrotic disorders, diabetes, or metabolic syndrome leading to liver fibrotic disorders.

12. A method of preparing a compound of formula (iv),



(iv),

the method comprising contacting a compound of formula (iii),




(iii),

with R^1NH_2 in the presence of a base or a Lewis acid, in a solvent,


wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted saturated cycloalkyl,

wherein R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl.


13. The method of claim 12, wherein R^2 is



14. The method of claim 12, wherein R^1 is




15. The method of claim 12, wherein the compound of formula (iii),



(iii),

is prepared by contacting of 2,4-dichloropyrimidine-5-carboxamide with R^2NH_2 in the presence of a base in a solvent.


16. The method of claim 15, wherein R^2 is



17. A method of preparing the crystal form of any one of claims 1 – 9,

the method comprising 1) dissolving Compound 1 in a first solvent at a first temperature; 2) adding a second solvent into the resulting solution; 3) cooling the solution to a second temperature; and 4) collecting the crystal form.

18. A compound of formula (iii),




(iii),

and tautomers thereof,

wherein R^2 is substituted or unsubstituted saturated cycloalkyl.

19. The compound of claim 18, wherein R^2 is



or .

20. The crystal form or solid form of any one of claims 1 – 9, for use in a method for treating or preventing interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus.

21. The crystal form or solid form of any one of claims 1 – 9, for use in a method for treating or preventing liver fibrotic disorders, diabetes, or metabolic syndrome leading to liver fibrotic disorders.